Cargando…

Prostate-Specific Membrane Antigen Expression on PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer: A Retrospective Observational Study

Monitoring therapy response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with novel hormonal therapies, taxanes, and newly approved therapies is crucial for optimizing treatment. [(68)Ga]Ga-prostate-specific membrane antigen (PSMA)-11 positron emission tomography/...

Descripción completa

Detalles Bibliográficos
Autores principales:	Calderoni, Letizia, Maietti, Elisa, Farolfi, Andrea, Mei, Riccardo, Louie, Karly S., Groaning, Michael, Fanti, Stefano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Society of Nuclear Medicine 2023
Materias:	Clinical Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241018/ https://www.ncbi.nlm.nih.gov/pubmed/36635087 http://dx.doi.org/10.2967/jnumed.122.264964

Ejemplares similares

A Retrospective Multicenter Analysis of the Incidence of Bone-Only Disease at PSMA PET/CT in Castration Resistant Prostate Cancer Patients
por: Serani, Francesca, et al.
Publicado: (2023)

(177)Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior (223)Ra (RALU Study)
por: Rahbar, Kambiz, et al.
Publicado: (2023)

PET/CT in Prostate Cancer
por: Evangelista, Laura, et al.
Publicado: (2023)

Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer
por: Vlachostergios, Panagiotis J., et al.
Publicado: (2021)

PARP Inhibitors and Radiometabolic Approaches in Metastatic Castration-Resistant Prostate Cancer: What’s Now, What’s New, and What’s Coming?
por: Marchetti, Andrea, et al.
Publicado: (2022)

Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter Study
por: Gafita, Andrei, et al.
Publicado: (2022)

PSMA PET/CT in Castration-Resistant Prostate Cancer: Myth or Reality?
por: Urso, Luca, et al.
Publicado: (2023)

Prognostic Evaluation of Metastatic Castration Resistant Prostate Cancer and Neuroendocrine Prostate Cancer with [(68)Ga]Ga DOTATATE PET-CT
por: Bilen, Mehmet Asim, et al.
Publicado: (2022)

Prostate-specific Membrane Antigen Based Antibody-drug Conjugates for Metastatic Castration-resistance Prostate Cancer
por: Niaz, Muhammad O, et al.
Publicado: (2020)

Narrative review: prostate-specific membrane antigen-radioligand therapy in metastatic castration-resistant prostate cancer
por: Lunger, Lukas, et al.
Publicado: (2021)

Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer
por: Hwang, Clara, et al.
Publicado: (2023)

PSMA PET for the Evaluation of Liver Metastases in Castration-Resistant Prostate Cancer Patients: A Multicenter Retrospective Study
por: Mattoni, Susanna, et al.
Publicado: (2022)

Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone
por: De Giorgi, Ugo, et al.
Publicado: (2014)

Early prostate-specific antigen response post-abiraterone as predictor of overall survival in metastatic castrate-resistant prostate cancer
por: Schiff, Joshua P., et al.
Publicado: (2019)

Assessment of a Clinical Trial–Derived Survival Model in Patients With Metastatic Castration-Resistant Prostate Cancer
por: Coquet, Jean, et al.
Publicado: (2021)

Histology and PSMA Expression on Immunohistochemistry in High-Risk Prostate Cancer Patients: Comparison with (68)Ga-PSMA PET/CT Features in Primary Staging
por: Vetrone, Luigia, et al.
Publicado: (2023)

Sensitivity of (18)F-fluorodihydrotestosterone PET-CT to count statistics and reconstruction protocol in metastatic castration-resistant prostate cancer
por: Cysouw, Matthijs C. F., et al.
Publicado: (2019)

Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer
por: Du, Yong, et al.
Publicado: (2017)

Chimeric Antigen Receptor T-Cell Therapy in Metastatic Castrate-Resistant Prostate Cancer
por: Perera, Mahasha P.J., et al.
Publicado: (2022)

Incidental prostate-specific membrane antigen-avid meningioma detected on (68)Ga–prostate-specific membrane antigen PET/CT
por: Jiang, James Yuheng, et al.
Publicado: (2021)

Incidental prostate-specific membrane antigen-avid glioblastoma detected on (68)Ga–prostate-specific membrane antigen PET/CT
por: Jiang, James Yuheng, et al.
Publicado: (2022)

Lutetium-177 prostate-specific membrane antigen-617 theranostics: New therapeutic hope in metastatic castrate-resistant prostate cancer?
por: Ranjan, Satish Kumar
Publicado: (2020)

Prognostic Value of (18)F-Choline PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Radium-223
por: Filippi, Luca, et al.
Publicado: (2020)

Assessment of the viability and treatment response of bone metastases in patients with metastatic castration-resistant prostate cancer using choline PET/CT
por: Kitajima, Kazuhiro, et al.
Publicado: (2021)

Targeted Approaches in Metastatic Castration-Resistant Prostate Cancer: Which Data?
por: Mosillo, Claudia, et al.
Publicado: (2022)

Understanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer: implications for clinical practice
por: Mizokami, Atsushi, et al.
Publicado: (2017)

Concordance between Response Assessment Using Prostate-Specific Membrane Antigen PET and Serum Prostate-Specific Antigen Levels after Systemic Treatment in Patients with Metastatic Castration Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
por: Han, Sangwon, et al.
Publicado: (2021)

Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide
por: Conteduca, Vincenza, et al.
Publicado: (2022)

Association of Chemotherapy, Enzalutamide, Abiraterone, and Radium 223 With Cognitive Function in Older Men With Metastatic Castration-Resistant Prostate Cancer
por: Alibhai, Shabbir M. H., et al.
Publicado: (2021)

Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer
por: Graf, Ryon P., et al.
Publicado: (2022)

The use of (68)Ga prostate-specific membrane antigen PET-CT in prostate cancer: diagnostic challenges and therapeutic opportunities
por: Franzese, Elisena, et al.
Publicado: (2021)

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2019)

Lutetium-177 Prostate-Specific Membrane Antigen-617 Treatment in Metastatic Castration-Resistant Prostate Adenocarcinoma: Results of Single-Center Experience
por: Maman, Adem
Publicado: (2023)

FDG PET-CT demonstration of metastatic neuroendocrine tumor of prostate
por: Liu, Yiyan
Publicado: (2008)

Outcomes Among African American and Non-Hispanic White Men With Metastatic Castration-Resistant Prostate Cancer With First-Line Abiraterone
por: Marar, Mallika, et al.
Publicado: (2022)

Pain Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with (223)Ra: PARABO, a Prospective, Noninterventional Study
por: Palmedo, Holger, et al.
Publicado: (2023)

Dendritic cells pulsed with prostate-specific membrane antigen in metastatic castration-resistant prostate cancer patients: a systematic review and meta-analysis
por: Mohammadzadeh, Mohammad, et al.
Publicado: (2018)

Renal outcomes of radioligand therapy: experience of (177)lutetium—prostate-specific membrane antigen ligand therapy in metastatic castrate-resistant prostate cancer
por: Gallyamov, Marat, et al.
Publicado: (2019)

Tumor Sink Effect with Prostate-Specific Membrane Antigen-Targeted Theranostics in Patients with Metastatic Castration-Resistant Prostate Cancer: Intra-Individual Evaluations
por: Burgard, Caroline, et al.
Publicado: (2023)

Utilization and Outcomes of Surgical Castration in Comparison to Medical Castration in Metastatic Prostate Cancer
por: Garje, Rohan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_n6mb8pbdqm3b8hg0t26tulqrdk